EMAIL THIS PAGE TO A FRIEND

Antimicrobial agents and chemotherapy

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.


PMID 25385112

Abstract

AZD0914 is a new spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor with potent in vitro antibacterial activity against key Gram-positive (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae), fastidious Gram-negative (Haemophilus influenzae and Neisseria gonorrhoeae), atypical (Legionella pneumophila), and anaerobic (Clostridium difficile) bacterial species, including isolates with known resistance to fluoroquinolones. AZD0914 works via inhibition of DNA biosynthesis and accumulation of double-strand cleavages; this mechanism of inhibition differs from those of other marketed antibacterial compounds. AZD0914 stabilizes and arrests the cleaved covalent complex of gyrase with double-strand broken DNA under permissive conditions and thus blocks religation of the double-strand cleaved DNA to form fused circular DNA. Whereas this mechanism is similar to that seen with fluoroquinolones, it is mechanistically distinct. AZD0914 exhibited low frequencies of spontaneous resistance in S. aureus, and if mutants were obtained, the mutations mapped to gyrB. Additionally, no cross-resistance was observed for AZD0914 against recent bacterial clinical isolates demonstrating resistance to fluoroquinolones or other drug classes, including macrolides, β-lactams, glycopeptides, and oxazolidinones. AZD0914 was bactericidal in both minimum bactericidal concentration and in vitro time-kill studies. In in vitro checkerboard/synergy testing with 17 comparator antibacterials, only additivity/indifference was observed. The potent in vitro antibacterial activity (including activity against fluoroquinolone-resistant isolates), low frequency of resistance, lack of cross-resistance, and bactericidal activity of AZD0914 support its continued development.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A8523
Amoxicillin, potency: ≥900 μg per mg
C16H19N3O5S
1031503
Amoxicillin, United States Pharmacopeia (USP) Reference Standard
C16H19N3O5S · 3H2O
75199
Azithromycin, analytical standard
C38H72N2O12
Y0000306
Azithromycin, European Pharmacopoeia (EP) Reference Standard
C38H72N2O12
1046056
Azithromycin, United States Pharmacopeia (USP) Reference Standard
C38H72N2O12 · 2H2O
Y0000637
Azithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
C38H72N2O12
Y0000641
Azithromycin for system suitability, European Pharmacopoeia (EP) Reference Standard
C38H72N2O12
1046067
Azithromycin Identity, United States Pharmacopeia (USP) Reference Standard
C38H72N2O12
A6848
Aztreonam, analytical standard
C13H17N5O8S2
1046205
Aztreonam, United States Pharmacopeia (USP) Reference Standard
C13H17N5O8S2
C0690500 Ceftazidime, European Pharmacopoeia (EP) Reference Standard
C22H22N6O7S2 · 5H2O
1362103
Levofloxacin, United States Pharmacopeia (USP) Reference Standard
C18H20FN3O4 · 0.5H2O
40922
Levofloxacin, analytical reference material
C18H20FN3O4
1392454
Meropenem, United States Pharmacopeia (USP) Reference Standard
C17H25N3O5S · 3H2O
M3761
Metronidazole, analytical standard
C6H9N3O3
46461
Metronidazole, VETRANAL, analytical standard
C6H9N3O3
M1850000
Metronidazole, European Pharmacopoeia (EP) Reference Standard
C6H9N3O3
PHR1052
Metronidazole, Pharmaceutical Secondary Standard; Certified Reference Material
C6H9N3O3